<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306773</url>
  </required_header>
  <id_info>
    <org_study_id>HKU-CP1</org_study_id>
    <nct_id>NCT01306773</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma Treatment in Severe 2009 H1N1 Infection</brief_title>
  <official_title>Convalescent Plasma Treatment in Patients With Severe 2009 H1N1 Infection: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of severe 2009 H1N1 infection with convalescent plasma will reduce mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presented with severe 2009 H1N1 infection responded poorly to antiviral agents.
      Meta-analysis of reports from 1918 H1N1 pandemic suggested that convalescent plasma might be
      an effective treatment option for patients with severe 2009 H1N1 infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Participants are followed until death or discharge from ICU (average 2 weeks)</time_frame>
    <description>mortality during hospitalization directly related to H1N1 2009 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication</measure>
    <time_frame>Participants are followed until death or discharge from ICU (average 2 weeks)</time_frame>
    <description>including pneumonia, ARDS, renal failure, heart failure and secondary infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>Participants are followed until death or discharge from ICU (average 2 weeks)</time_frame>
    <description>days of stay in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events secondary to the convalescent plasma treatment</measure>
    <time_frame>Participants are followed until death or discharge from ICU (average 2 weeks)</time_frame>
    <description>Allergic reaction (including anaphylaxis), acute renal failure, fluid overload</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on respiratory support</measure>
    <time_frame>Participants are followed until death or discharge from ICU (average 2 weeks)</time_frame>
    <description>including ventilator, CPAP and BiPAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in viral load</measure>
    <time_frame>Participants are followed until death or discharge from ICU (average 2 weeks)</time_frame>
    <description>Daily measurement of H1N1 2009 viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cytokine level</measure>
    <time_frame>Participants are followed until death or discharge from ICU (average 2 weeks)</time_frame>
    <description>daily measurement of cytokine level (serum)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Influenza A</condition>
  <arm_group>
    <arm_group_label>H1N1 convalescent plasma and oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Oseltamivir alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oseltamivir 75mg bid during ICU hospitalization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H1N1 convalescent plasma and oseltamivir</intervention_name>
    <description>Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing &gt;= 1:160 of neutralizing antibody to Pandemic influenza A H1N1</description>
    <arm_group_label>H1N1 convalescent plasma and oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Oseltamivir alone</intervention_name>
    <description>Oral Oseltamivir 75mg bid during ICU hospitalization</description>
    <arm_group_label>Oral Oseltamivir alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients â‰¥ 18 years old with written informed consent given by patient or
             next-of-kin

          -  laboratory confirmatory diagnosis of 2009 H1N1 infection by positive RT-PCR from
             respiratory specimens

          -  required intensive care within 7 days of onset of symptoms

        Exclusion Criteria:

          -  age 18 years old or below

          -  known hypersensitivity to immune globulin

          -  known IgA deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan FN HUNG, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong SAR</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>March 1, 2011</last_update_submitted>
  <last_update_submitted_qc>March 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Ivan FN Hung</name_title>
    <organization>The University of Hong Kong</organization>
  </responsible_party>
  <keyword>Influenza A</keyword>
  <keyword>convalescent plasma</keyword>
  <keyword>death</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

